Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced that Dr. Charles Morris has joined the company as chief medical officer as it advances its oncology pipeline toward clinical development.
Prelude Therapeutics Appoints Charles Morris as Chief Medical Officer Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) will present preclinical data on its experimental breast cancer drug candidate at the American Association for Cancer Research Annual Meeting 2026, the …
Prelude Therapeutics to Present Breast Cancer Drug Data at AACR 2026 Read More WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) reported its financial results for the year ended December 31, 2025, and provided updates on its oncology drug development pipeline, including regulatory …
Prelude Therapeutics Reports 2025 Results and Advances Oncology Pipeline Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) said the U.S. Food and Drug Administration has cleared its investigational new drug application for PRT12396, allowing the company to begin a …
FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) reported third-quarter 2025 financial results and outlined key progress across its oncology pipeline, including two drug candidates now moving toward clinical development …
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced a series of strategic updates aimed at sharpening its development priorities and extending its financial runway. The biotechnology company has executed …
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has entered into an exclusive option agreement with Incyte Corporation (Nasdaq: INCY) for its mutant-selective JAK2V617F JH2 inhibitor program, a next-generation therapy …
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the publication of two abstracts featuring preclinical data from its JAK2V617F mutant-selective inhibitor program and CALR-targeted degrader antibody conjugates (DACs) discovery …
Prelude Therapeutics Highlights Groundbreaking Blood Cancer Research at ASH 2025 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the appointment of Katina Dorton to its Board of Directors, effective immediately. Dorton brings more than 30 years of experience in …
Prelude Therapeutics Appoints Katina Dorton to Board of Directors Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has shifted its strategic focus toward its oral SMARCA2 degrader, PRT7732, while reporting narrower second-quarter losses and steady progress across its oncology …
Prelude Therapeutics Refocuses SMARCA2 Program, Cuts Quarterly Losses Read More